At what hemoglobin level should anemia be corrected and what target range should be aimed for in patients with heart failure with reduced ejection fraction (HFrEF)?

Hemoglobin Correction in HFrEF: Thresholds and Targets

In patients with HFrEF, investigate and treat underlying causes of anemia when hemoglobin falls below 110 g/L (11 g/dL), but do NOT aggressively target hemoglobin correction with erythropoiesis-stimulating agents, as this increases thrombotic events without mortality benefit.

Critical Hemoglobin Thresholds

The evidence establishes distinct hemoglobin levels that trigger different clinical actions:

When to Investigate (Hemoglobin <110 g/L or Hematocrit <35%)

All patients with HFrEF and hemoglobin below 110 g/L should undergo comprehensive evaluation for reversible causes 1. This threshold represents where increased adverse events consistently appear in the literature. The investigation must include:

• Complete blood count with indices
• Iron studies (ferritin, transferrin saturation, serum iron)
• Vitamin B12 and folate levels
• Assessment for chronic blood loss (stool occult blood, upper/lower GI evaluation if indicated)
• Renal function (creatinine, eGFR)
• Inflammatory markers if chronic disease suspected

Severe Symptomatic Anemia (Hemoglobin <90 g/L)

When hemoglobin drops below 90 g/L AND the patient has advanced heart failure symptoms, consider blood transfusion after correcting substrate deficiencies 1. This is a clinical decision based on symptom severity, not an automatic trigger.

What NOT to Target

Avoid Erythropoiesis-Stimulating Agents

The 2022 AHA/ACC/HFSA guidelines explicitly recommend AGAINST using erythropoietin or darbepoetin to treat anemia in HFrEF 2. This strong recommendation stems from high-quality evidence showing:

• A randomized trial of 2,278 patients with darbepoetin alpha demonstrated no mortality benefit
• Increased thrombotic events, including stroke
• A meta-analysis of 13 trials confirmed these findings 2

The 2015 Canadian guidelines concordantly state: "We recommend erythropoiesis stimulating agents not be routinely used to treat anemia in HF (Strong Recommendation; High-Quality Evidence)" 3.

Optimal Hemoglobin Range (Prognostic, Not Treatment Target)

Recent high-quality research reveals that the lowest risk of death and HF hospitalization occurs at hemoglobin concentrations of approximately 14 g/dL in women and 15 g/dL in men 4. This analysis of 25,003 HFrEF patients shows:

• WHO anemia thresholds (12 g/dL women, 13 g/dL men) are associated with highest risk
• Even hemoglobin 0-1 g/dL above WHO thresholds carries excess risk
• Hemoglobin ≥2 g/dL above WHO thresholds shows optimal outcomes

Critical caveat: These are observational associations, NOT treatment targets. Attempting to artificially raise hemoglobin to these levels with ESAs causes harm.

Treatment Algorithm

Step 1: Correct Substrate Deficiencies (Class I Recommendation)

Always treat iron, vitamin B12, or folate deficiencies when identified 1:

• Iron deficiency: Use intravenous iron (ferric carboxymaltose preferred)

  • Oral iron is inadequate in HF due to poor absorption 2
  • IV iron reduces HF hospitalizations (AFFIRM-AHF: RR 0.74,95% CI 0.58-0.94) 2
  • The 2015 Canadian guidelines suggest iron supplementation to improve functional capacity 3

• B12/Folate deficiency: Standard replacement therapy

Step 2: Address Underlying Causes

• Treat chronic blood loss sources
• Optimize renal function where possible
• Manage inflammatory conditions
• Review medications that may contribute (NSAIDs, anticoagulants)

Step 3: Symptomatic Management

For hemoglobin <90 g/L with severe symptoms:

• Consider transfusion cautiously
• Only after substrate correction
• Balance against volume overload risk in HF

Step 4: Specialist Referral

Patients with severe chronic kidney disease and anemia should be referred to nephrology 3. The intersection of HFrEF, CKD, and anemia requires specialized management.

Common Pitfalls to Avoid

1. Do not use ESAs to "normalize" hemoglobin - This increases stroke risk without survival benefit
2. Do not use oral iron alone - It's inadequate in HF due to absorption issues
3. Do not ignore hemoglobin 110-120 g/L as "normal enough" - This range still carries prognostic information and may indicate iron deficiency 4
4. Do not transfuse reflexively at 90 g/L - Consider symptoms, volume status, and whether substrate deficiencies have been corrected first
5. Do not forget that anemia may reflect disease severity - In HFrEF with CKD, hemoglobin may be a marker of congestion and renal dysfunction rather than a treatment target 5, 6

Key Divergence in Evidence

The older 2007 Canadian guidelines 1 suggested bone marrow-stimulating agents "may be considered" for severe symptomatic anemia, but this was before the definitive RED-HF trial. The 2022 AHA/ACC/HFSA guidelines 2 and 2015 Canadian update 3 supersede this with strong recommendations against ESAs based on high-quality RCT evidence showing harm.